Ahmedabad: Zydus Lifesciences has announced that the company has received the Establishment Inspection Report (EIR) from the U.S. Food and Drugs Administration (USFDA) for an inspection conducted at its manufacturing facility located at Baddifrom 4th to 13th August 2025. In August, the company received four observations. Read also:Zydus Lifesciences gets 4 USFDA observations for Baddi plant The EIR has classified the facility as Voluntary Action Indicated (VAI). The USFDA has concluded this inspection as closed. Read also:Zydus bags Health Canada approval for Mesalamine suppositories for active ulcerative proctitis Zydus Lifesciences Ltd.is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!